Key facts
- Notable investors include Beijing Jinhuifeng Investment Management, Beijing Shengshi Hongming Investment Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Yongshengbuluo
- ·The full record, as it builds
Funding rounds
No funding rounds for Yongshengbuluo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yongshengbuluo
Developer of new immune cell and stem cell drugs based in Huangshan, China. The company specialises in gene editing, cell drug development, and clinical research.
- Sector
- Healthcare
- HQ
- Huangshan, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Yongshengbuluo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yongshengbuluo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yongshengbuluo in its N-PORT filings yet. We sweep new filings monthly.